Biomarker Trends in Breast Cancer Research
Research Summaries from the San Antonio Breast Cancer Symposium
Biomarker Trends in Breast Cancer Research
Research Summaries from the San Antonio Breast Cancer Symposium
As our knowledge of biomarkers increases, new studies are uncovering promising news on treating breast cancer. This emerging technology is already helping to predict which cancers – and which patients – will respond best to specific drugs. Molecular biologist and oncology expert Dr. Jason Hill summarizes six important studies presented at the 2009 San Antonio Breast Cancer Symposium. All focusing on biomarkers for breast cancer, the studies examined mechanisms of action and novel drug combinations that may unlock breakthroughs in treatment. Dr. Hill discusses the implications and questions that will drive future R&D efforts to develop targeted breast cancer therapies.
About the Author
Jason Hill, PhD
Associate Director, External Science Affairs, Quintiles
Dr. Jason Hill works with Quintiles’ Central Laboratories, using his experience in tissue-based biomarkers to engage clinical and translational scientists in biopharma. Dr. Hill was formerly director of molecular biology at Targeted Molecular Diagnostics (TMD), a company specializing in the development and deployment of tissue-based biomarker assays for oncology clinical trials. Quintiles acquired TMD in 2008. Dr. Hill received his PhD in molecular genetics from the University of Illinois at Chicago and completed his post-doctoral studies at the Cleveland Clinic Foundation in 2004. He developed model systems for screening of chemical libraries to identify p53 modulating compounds. A p53 activating compound that he helped characterize is currently in clinical studies.
